Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer

References

• World Health Organization [webpage on the Internet]WHO Cancer Fact Sheets2015 Available from: http://www.who.int/mediacentre/factsheets/fs297/en/Accessed September 5, 2017
   Google Scholar
• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• RiazSPLuchtenborgMCouplandVHSpicerJPeakeMDMollerHTrends in incidence of small cell lung cancer and all lung cancerLung Cancer201275328028421893364
   PubMed Web of Science ®Google Scholar
• Institute NC [webpage on the Internet]SEER Cancer Statistics Review2012 Available from: https://seer.cancer.gov/archive/csr/1975_2012/browse_csr.php?sectionSEL=15&pageSEL=sect_15_table.28.htmlAccessed September 5, 2017
   Google Scholar
• GoldstrawPChanskyKCrowleyJInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating InstitutionsInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating InstitutionsThe IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancerJ Thorac Oncol2016111395126762738
   PubMed Web of Science ®Google Scholar
• DetterbeckFCThe eighth edition TNM stage classification for lung cancer: what does it mean on main street?J Thorac Cardiovasc Surg2018155135635929061464
   PubMed Web of Science ®Google Scholar
• DetterbeckFCBoffaDJKimAWTanoueLTThe eighth edition lung cancer stage classificationChest2017151119320327780786
   PubMed Web of Science ®Google Scholar
• RobinsonLARuckdeschelJCWagnerHJrStevensCWAmerican College of Chest PhysiciansTreatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)Chest20071323 suppl243S265S17873172
   PubMed Web of Science ®Google Scholar
• EberhardtWEEDe RuysscherDWederWESMO consensus guidelines: locally-advanced stage III non-small-cell lung cancer (NSCLC)Ann Oncol20152681573158825897013
   PubMed Web of Science ®Google Scholar
• RamnathNDillingDJHarrisLJTreatment of stage III non-small cell lung cancer. 3rd ed, American College of Chest Physicians evidence-based clinical practice guidelinesChest20131435 supple314Se340S23649445
   PubMed Web of Science ®Google Scholar
• RobinsonCGPatelAPBradleyJDPostoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the national cancer data baseJ Clin Oncol201533887087625667283
   PubMed Web of Science ®Google Scholar
• DetterbeckFCWhat to do with “surprise” N2? Intraoperative management of patients with non-small cell lung cancerJ Thorac Oncol20083328930218317073
   PubMed Web of Science ®Google Scholar
• ChoHJKimSRKimHRModern outcome and risk analysis of surgically resected occult N2 non-small cell lung cancerAnn Thorac Surg20149761920192524768044
   PubMed Web of Science ®Google Scholar
• GuoSXJianYChenYLCaiYZhangQYTouFFNeoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for resectable stage III non-small-cell lung cancer: a meta-analysisSci Rep201663438827677242
   PubMed Web of Science ®Google Scholar
• RuschVCrowleyJGirouxDJInternational Staging CommitteeCancer Research and BiostatisticsObservers to the CommitteeParticipating InstitutionsThe IASLC lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancerJ Thorac Oncol20072760361217607115
   PubMed Web of Science ®Google Scholar
• YoonSMShaikhTHallmanMTherapeutic management options for stage III non-small cell lung cancerWorld J Oncol20178112028983377
   PubMedGoogle Scholar
• CurranWJPaulusRLangerCJSequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410J Natl Cancer Inst2011103191452146021903745
   PubMedGoogle Scholar
• StewartRMorrowMHammondSAIdentification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibodyCancer Immunol Res2015391052106225943534
   PubMed Web of Science ®Google Scholar
• KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol20082667770418173375
   PubMed Web of Science ®Google Scholar
• FifeBTPaukenKEThe role of the PD-1 pathway in autoimmunity and peripheral toleranceAnn N Y Acad Sci20111217455921276005
   PubMed Web of Science ®Google Scholar
• SharmaPHu-LieskovanSWargoJARibasAPrimary, adaptive, and acquired resistance to cancer immunotherapyCell2017168470772328187290
   PubMed Web of Science ®Google Scholar
• Garcia-DiazAShinDSMorenoBHInterferon receptor signaling pathways regulating PD-L1 and PD-L2 expressionCell Rep20171961189120128494868
   PubMed Web of Science ®Google Scholar
• ParkJJOmiyaRMatsumuraYB7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell toleranceBlood201011681291129820472828
   PubMed Web of Science ®Google Scholar
• MuCYHuangJAChenYChenCZhangXGHigh expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturationMed Oncol201128368268820373055
   PubMed Web of Science ®Google Scholar
• PowlesTO’DonnellPHMassardCEfficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label studyJAMA Oncol201739e17241128817753
   PubMed Web of Science ®Google Scholar
• MassardCGordonMSSharmaSSafety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancerJ Clin Oncol201634263119312527269937
   PubMed Web of Science ®Google Scholar
• AntoniaSJBrahmerJRKhleifSPhase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)Ann Oncol201627suppl 61216
   Google Scholar
• AntoniaSJKimSWApiraAISafety and clinical activity of durvalumab (MEDI4736), an anti-PD-LI antibody, in treatment-naive patients with advanced non-small-cell lung cancerJ Clin Oncol201634suppl8032
   Google Scholar
• GarassinoMCVansteenkisteJFKimJDurvalumab in ≥ 3rd-line locally advanced or metastatic, EGFR/ALK wild-type NSCLC: results from the phase 2 ATLANTIC studyWorld Conf Lung Cancer2016S10S11
   Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• RittmeyerABarlesiFWaterkampDOAK Study GroupAtezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialLancet20173891006625526527979383
   PubMed Web of Science ®Google Scholar
• ReckMRodriguez-AbreuDRobinsonAGKEYNOTE-024 InvestigatorsPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med2016375191823183327718847
   PubMed Web of Science ®Google Scholar
• KGaA M [webpage on the Internet]Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer2018 Available from: https://www.emdgroup.com/en/news/update-javelin-lung-15-02-2018.htmlAccessed March 23, 2018
   Google Scholar
• BezjakATeminSFranklinGDefinitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guidelineJ Clin Oncol201533182100210525944914
   PubMed Web of Science ®Google Scholar
• DillmanROSeagrenSLPropertKJA randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancerN Engl J Med1990323149409452169587
   PubMed Web of Science ®Google Scholar
• SauseWKolesarPTaylorSIFinal results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology GroupChest2000117235836410669675
   PubMed Web of Science ®Google Scholar
• FournelPRobinetGThomasPGroupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-CancérologieRandomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 studyJ Clin Oncol200523255910591716087956
   PubMed Web of Science ®Google Scholar
• ZatloukalPPetruzelkaLZemanovaMConcurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized studyLung Cancer2004461879815364136
   PubMed Web of Science ®Google Scholar
• AuperinALe PechouxCRollandEMeta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancerJ Clin Oncol201028132181219020351327
   PubMed Web of Science ®Google Scholar
• VokesEEHerndonJE2ndKelleyMJCancer and Leukemia Group BInduction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: cancer and leukemia group BJ Clin Oncol200725131698170417404369
   PubMed Web of Science ®Google Scholar
• GandaraDRChanskyKAlbainKSLong-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504)Clin Lung Cancer20068211612117026812
   PubMed Web of Science ®Google Scholar
• HannaNNeubauerMYiannoutsosCHoosier Oncology GroupUS OncologyPhase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. OncologyJ Clin Oncol200826355755576019001323
   PubMed Web of Science ®Google Scholar
• BelaniCPChoyHBonomiPCombined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocolJ Clin Oncol200523255883589116087941
   PubMed Web of Science ®Google Scholar
• KellyKChanskyKGasparLEPhase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023J Clin Oncol200826152450245618378568
   PubMed Web of Science ®Google Scholar
• HoangTDahlbergSESchillerJHRandomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 studyJ Clin Oncol201230661662222271472
   PubMed Web of Science ®Google Scholar
• BradleyJDPaulusRKomakiRStandard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 studyLancet Oncol201516218719925601342
   PubMed Web of Science ®Google Scholar
• WozniakAJMoonJThomasCRJrA pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage III non-small-cell lung cancer: SWOG S0533Clin Lung Cancer201516534034725703100
   PubMed Web of Science ®Google Scholar
• SwannJBSmythMJImmune surveillance of tumorsJ Clin Invest200711751137114617476343
   PubMed Web of Science ®Google Scholar
• MoleRHWhole body irradiation; radiobiology or medicine?Br J Radiol19532630523424113042090
   PubMed Web of Science ®Google Scholar
• FormentiSCDemariaSSystemic effects of local radiotherapyLancet Oncol200910771872619573801
   PubMed Web of Science ®Google Scholar
• BlanquicettCSaifMWBuchsbaumDJAntitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effectsClin Cancer Res20051124 pt 18773878116361565
   PubMed Web of Science ®Google Scholar
• DemariaSNgBDevittMLIonizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediatedInt J Radiat Oncol Biol Phys200458386287014967443
   PubMed Web of Science ®Google Scholar
• ShiraishiKIshiwataYNakagawaKEnhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alphaClin Cancer Res20081441159116618281550
   PubMed Web of Science ®Google Scholar
• GalluzziLMaiuriMCVitaleICell death modalities: classification and pathophysiological implicationsCell Death Differ20071471237124317431418
   PubMed Web of Science ®Google Scholar
• ReitsEAHodgeJWHerbertsCARadiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJ Exp Med200620351259127116636135
   PubMed Web of Science ®Google Scholar
• ObeidMPanaretakisTJozaNCalreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosisCell Death Differ200714101848185017657249
   PubMed Web of Science ®Google Scholar
• ObeidMTesniereAGhiringhelliFCalreticulin exposure dictates the immunogenicity of cancer cell deathNat Med2007131546117187072
   PubMed Web of Science ®Google Scholar
• KeppOTesniereASchlemmerFImmunogenic cell death modalities and their impact on cancer treatmentApoptosis200914436437519145485
   PubMed Web of Science ®Google Scholar
• ApetohLGhiringhelliFTesniereAToll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNat Med20071391050105917704786
   PubMed Web of Science ®Google Scholar
• ChakrabortyMAbramsSICamphausenKIrradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapyJ Immunol2003170126338634712794167
   PubMed Web of Science ®Google Scholar
• UnoMOtsukiTYataKParticipation of Fas-mediated apoptotic pathway in KB, a human head and neck squamous cell carcinoma cell line, after irradiationInt J Oncol200220361762211836578
   PubMed Web of Science ®Google Scholar
• KlugFPrakashHHuberPELow-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapyCancer Cell201324558960224209604
   PubMed Web of Science ®Google Scholar
• WuCYYangLHYangHYEnhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumorsClin Cancer Res201420364465724300786
   PubMed Web of Science ®Google Scholar
• StephensTCCurrieGAPeacockJHRepopulation of gamma- irradiated Lewis lung carcinoma by malignant cells and host macrophage progenitorsBr J Cancer1978385573582728347
   PubMed Web of Science ®Google Scholar
• AhnGOBrownJMMatrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cellsCancer Cell200813319320518328424
   PubMed Web of Science ®Google Scholar
• DovediSJAdlardALLipowska-BhallaGAcquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockadeCancer Res201474195458546825274032
   PubMed Web of Science ®Google Scholar
• KerstenKSalvagnoCde VisserKEExploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapyFront Immunol2015651626500653
   PubMed Web of Science ®Google Scholar
• de BiasiARVillena-VargasJAdusumilliPSCisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidenceClin Cancer Res201420215384539125204552
   PubMed Web of Science ®Google Scholar
• GhiringhelliFMenardCPuigPEMetronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunol Immunother200756564164816960692
   PubMed Web of Science ®Google Scholar
• ShevchenkoIKarakhanovaSSoltekSLow-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancerInt J Cancer201313319810723233419
   PubMed Web of Science ®Google Scholar
• KodumudiKNWoanKGilvaryDLSahakianEWeiSDjeuJYA novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearersClin Cancer Res201016184583459420702612
   PubMed Web of Science ®Google Scholar
• BoyerMJGuLWangXToxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancerLung Cancer201698767827393510
   PubMed Web of Science ®Google Scholar
• ButtsCSocinskiMAMitchellPLSTART Trial TeamTecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trialLancet Oncol2014151596824331154
   PubMed Web of Science ®Google Scholar
• WurzGTGutierrezAMGreenbergBEAntitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse modelJ Transl Med2013116423496860
   PubMed Web of Science ®Google Scholar
• MacLeanGDMilesDWRubensRDReddishMALongeneckerBMEnhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamideJ Immunother Emphasis Tumor Immunol19961943093168877724
   PubMed Web of Science ®Google Scholar
• ButtsCMurrayNMaksymiukARandomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancerJ Clin Oncol200523276674668116170175
   PubMed Web of Science ®Google Scholar
• ButtsCMaksymiukAGossGUpdated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trialJ Cancer Res Clin Oncol201113791337134221744082
   PubMed Web of Science ®Google Scholar
• GiacconeGBazhenovaLANemunaitisJA phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancerEur J Cancer201551162321232926283035
   PubMed Web of Science ®Google Scholar
• KatakamiNHidaTNokiharaHPhase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancerLung Cancer2017105233028236981
   PubMed Web of Science ®Google Scholar
• AntoniaSJVillegasADanielDDurvalumab after chemo-radiotherapy in stage III non-small-cell lung cancerN Engl J Med2017377201919192928885881
   PubMed Web of Science ®Google Scholar
• Administration FnD [webpage on the Internet]FDA Expands Approval of Imfinzi to Reduce the Risk of Non-Small Cell Lung Cancer Progressing2018 Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm597217.htmAccessed March 23, 2018
   Google Scholar
• Medicine USNLo [webpage on the Internet]Nivolumab After Surgery and Chemotherapy in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL)2018 Available from: https://clinicaltrials.gov/ct2/show/NCT02595944?term=ANVIL&rank=1Accessed March 23, 2018
   Google Scholar
• Medicine USNLo [webpage on the Internet]Cisplatin and Etoposide Plus Radiation Followed by Nivolumab/Placebo for Locally Advanced NSCLC Available from: https://www.clinicaltrials.gov/ct2/show/NCT02768558?term=NCT02768558&rank=1Accessed December 18, 2017
   Google Scholar
• Medicine USNLo [webpage on the Internet]Consolidation Pembroli-zumab Following Chemoradiation in Patients with Inoperable/Unresectable Stage III NSCLC Available from: https://clinicaltrials.gov/ct2/show/NCT02343952?term=02343952&rank=1Accessed December 18, 2017
   Google Scholar
• Medicine USNLo [webpage on the Internet]NIvolumab COmbination with Standard First-Line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma (NICOLAS) Available from: https://www.clinicaltrials.gov/ct2/show/NCT02434081?term=NCT02434081&rank=1Accessed December 18, 2017
   Google Scholar
• NaiyerRAPetersSImmunotherapy for unresectable stage III non-small-cell lung cancerN Engl J Med2017377201986198829141165
   PubMed Web of Science ®Google Scholar
• PatelSPKurzrockRPD-L1 expression as a predictive biomarker in cancer immunotherapyMol Cancer Ther201514484785625695955
   PubMed Web of Science ®Google Scholar
• LeeCKManJLordSCheckpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer – a meta-analysisJ Thorac Oncol201712240340727765535
   PubMed Web of Science ®Google Scholar
• MauguenAPignonJPBurdettSSurrogate Lung Project Collaborative GroupSurrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients’ dataLancet Oncol201314761962623680111
   PubMed Web of Science ®Google Scholar
• Medicine USNLo [webpage on the Internet]Neoadjuvant Chemoradiation Plus Pembrolizumab Followed by Consolidation Pembrolizumab in NSCLC Available from: https://www.clinicaltrials.gov/ct2/show/NCT02987998?term=NCT02987998&rank=1Accessed December 18, 2017
   Google Scholar
• Medicine USNLo [webpage on the Internet]Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients with Stage II-IIIB Non-Small Cell Lung Cancer Available from: https://www.clinicaltrials.gov/ct2/show/NCT02621398?term=NCT02621398&rank=1Accessed December 18, 2017
   Google Scholar
• Medicine USNLo [webpage on the Internet]BLP25 Liposome Vaccine and Bevacizumab after Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Available from: https://www.clinicaltrials.gov/ct2/show/NCT00828009?term=NCT00828009&rank=1Accessed December 18, 2017
   Google Scholar
• Medicine USNLo [webpage on the Internet]A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer Available from: https://www.clinicaltrials.gov/ct2/show/NCT02662634?term=NCT02662634&rank=1Accessed December 18, 2017
   Google Scholar
• AminADudekAZLoganTFSurvival with AGS-003, an autolo-gous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study resultsJ Immunother Cancer201531425901286
   PubMed Web of Science ®Google Scholar
• AntoniaSGoldbergSBBalmanoukianASafety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyLancet Oncol201617329930826858122
   PubMed Web of Science ®Google Scholar